Browse by author
Lookup NU author(s): Dr Mark Verrill
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
We investigated whether the pharmacokinetics and tolerability of gefitinib were altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two open, parallel-group, multicenter studies.In Study 1, subjects with normal hepatic function or mild, moderate, or severe hepatic impairment (Child-Pugh criteria) due to cirrhosis received single-dose gefitinib 250 mg (n = 10 per group). In Study 2, patients with solid malignant tumors with normal liver biochemistry (n = 18), moderate (n = 16), or severe (n = 7) hepatic impairment (liver biochemistry tests) due to metastases received gefitinib 250 mg daily for 28 days.In Study 1, the geometric mean area under the plasma concentration-time curve (AUC) for gefitinib was significantly higher in patients with hepatic impairment compared with healthy subjects; hepatic impairment was associated with reduced gefitinib plasma clearance, longer half-life, and reduced plasma metabolite levels. In Study 2, the geometric mean gefitinib steady-state AUC during the 24-h dosing interval was slightly, but not significantly, higher in patients with moderate hepatic impairment; there were, however, no significant differences between groups in gefitinib and metabolite pharmacokinetic parameters. In both studies, gefitinib was well tolerated across all cohorts.We conclude that the effect of hepatic impairment on gefitinib pharmacokinetics depends on the underlying etiology of that impairment and its classification.
Author(s): Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H, Twelves C
Publication type: Article
Publication status: Published
Journal: Cancer Chemotherapy and Pharmacology
Year: 2011
Volume: 68
Issue: 6
Pages: 1485-1495
Print publication date: 13/04/2011
ISSN (print): 0344-5704
ISSN (electronic): 1432-0843
Publisher: Springer
URL: http://dx.doi.org/10.1007/s00280-011-1611-2
DOI: 10.1007/s00280-011-1611-2
Altmetrics provided by Altmetric
